XNAS
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
LTGO’s massive -5897.83% EPS surprise highlights extreme volatility and lack of profitability, making its $1.38B valuation speculative without clear positive earnings momentum.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 | Q2 2026 | -0.46 | -27.59 | -5897.83% | $0 | ❌ Miss | +0.00% | — | — |
Showing last 1 quarters.